Evonik Evonik

X
[{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"AllianceRx Walgreens","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AllianceRx Walgreens Prime Relaunches Exclusive Partnership for the Distribution of Cystaran\u00ae (cysteamine ophthalmic solution) 0.44%","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Leadiant Biosciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            As an exclusive partner, AllianceRx Walgreens Prime is able to offer end-to-end solutions for Leadiant Biosciences and Cystaran patients. Cystaran, a topical ophthalmic therapy for the treatment of corneal cystine crystals in patients with cystinosis.

            Lead Product(s): Cysteamine Hydrochloride

            Therapeutic Area: Genetic Disease Product Name: Cystaran

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: AllianceRx Walgreens

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY